Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
4.990
+0.280 (5.94%)
Nov 21, 2024, 12:43 PM EST - Market open

Lipocine Statistics

Total Valuation

Lipocine has a market cap or net worth of $26.69 million. The enterprise value is $5.52 million.

Market Cap 26.69M
Enterprise Value 5.52M

Important Dates

The last earnings date was Thursday, November 7, 2024, before market open.

Earnings Date Nov 7, 2024
Ex-Dividend Date n/a

Share Statistics

Lipocine has 5.35 million shares outstanding. The number of shares has increased by 1.56% in one year.

Current Share Class 5.35M
Shares Outstanding 5.35M
Shares Change (YoY) +1.56%
Shares Change (QoQ) +0.08%
Owned by Insiders (%) 2.91%
Owned by Institutions (%) 10.24%
Float 5.19M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 3.17
Forward PS 17.55
PB Ratio 1.32
P/TBV Ratio 1.32
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 0.70
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 12.97, with a Debt / Equity ratio of 0.01.

Current Ratio 12.97
Quick Ratio 12.59
Debt / Equity 0.01
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -19.50% and return on invested capital (ROIC) is -15.79%.

Return on Equity (ROE) -19.50%
Return on Assets (ROA) -14.56%
Return on Capital (ROIC) -15.79%
Revenue Per Employee $466,054
Profits Per Employee -$238,593
Employee Count 17
Asset Turnover 0.35
Inventory Turnover n/a

Taxes

In the past 12 months, Lipocine has paid $1,236 in taxes.

Income Tax 1,236
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +70.04% in the last 52 weeks. The beta is 1.19, so Lipocine's price volatility has been higher than the market average.

Beta (5Y) 1.19
52-Week Price Change +70.04%
50-Day Moving Average 5.08
200-Day Moving Average 5.28
Relative Strength Index (RSI) 41.13
Average Volume (20 Days) 26,843

Short Selling Information

The latest short interest is 75,199, so 1.41% of the outstanding shares have been sold short.

Short Interest 75,199
Short Previous Month 107,537
Short % of Shares Out 1.41%
Short % of Float 1.45%
Short Ratio (days to cover) 2.80

Income Statement

In the last 12 months, Lipocine had revenue of $7.92 million and -$4.06 million in losses. Loss per share was -$0.77.

Revenue 7.92M
Gross Profit 7.92M
Operating Income -5.29M
Pretax Income -8.49M
Net Income -4.06M
EBITDA -5.26M
EBIT -5.29M
Loss Per Share -$0.77
Full Income Statement

Balance Sheet

The company has $19.82 million in cash and $153,365 in debt, giving a net cash position of $19.67 million or $3.68 per share.

Cash & Cash Equivalents 19.82M
Total Debt 153,365
Net Cash 19.67M
Net Cash Per Share $3.68
Equity (Book Value) 19.12M
Book Value Per Share 3.57
Working Capital 18.92M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$4.95 million and capital expenditures -$89,234, giving a free cash flow of -$5.03 million.

Operating Cash Flow -4.95M
Capital Expenditures -89,234
Free Cash Flow -5.03M
FCF Per Share -$0.94
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -66.82% and -51.19%.

Gross Margin 100.00%
Operating Margin -66.82%
Pretax Margin -51.18%
Profit Margin -51.19%
EBITDA Margin -66.39%
EBIT Margin -66.82%
FCF Margin -98.48%

Dividends & Yields

Lipocine does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -1.56%
Shareholder Yield -1.56%
Earnings Yield -16.11%
FCF Yield -19.99%

Analyst Forecast

The average price target for Lipocine is $10.00, which is 100.40% higher than the current price. The consensus rating is "Strong Buy".

Price Target $10.00
Price Target Difference 100.40%
Analyst Consensus Strong Buy
Analyst Count 1
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on May 12, 2023. It was a reverse split with a ratio of 0.0588235:1.

Last Split Date May 12, 2023
Split Type Reverse
Split Ratio 0.0588235:1

Scores

Lipocine has an Altman Z-Score of -3.97 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -3.97
Piotroski F-Score 1